CS MEDICA A/S Plans Stock Spin-Off and Listing of CANNORDIC A/S

EQS-Ad-hoc: CS MEDICA / Key word(s): IPO
CS MEDICA A/S Plans Stock Spin-Off and Listing of CANNORDIC A/S

10-Jun-2024 / 14:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

CS MEDICA A/S, a pioneering MedTech company specializing in innovative
substance-based medical devices containing bioactive CBD, today announced
its plans to spin off and list its subsidiary CANNORDIC A/S on the German
Stock Market (Intention to Float).

CS MEDICA ("CS MEDICA" or "The Company") aims to elevate the value of CS
MEDICA's shares, targeting a preliminary valuation of CANNORDIC of MDKK 224.
This is a Compliant Publication according to Article 17 MAR of Regulation
(EU) No 596/2014.

The Board Members of CS MEDICA, with ISIN DK0061668225, announced the
approval to spin off its wholly-owned subsidiary CANNORDIC A/S and to
initiate preparations for a separate listing on one of the stock
exchange-regulated trading venues in Germany.

Based on the pre-market sounding conducted during several roadshows in
different German cities and the expressions of interest from institutional
and semi-institutional investors, CS MEDICA anticipates raising up to MDKK
45 (EUR 6 million) in the pre-IPO phase of the spin-off. As part of the
initial public offering (IPO), the first step involves placing up to 20% of
CANNORDIC A/S shares with institutional and semi-institutional investors
during the pre-IPO phase. The management will continuously evaluate the
placement of additional shares during the post-market launch, maintaining
the majority of the share capital of CANNORDIC A/S. This strategic move aims
to secure initial investment and generate interest from key market players
before the shares are publicly available.

Key Highlights:

* Spin-off Details: Up to 20% of CANNORDIC A/S shares will be spun off.

  * Valuation and Funding: Pre-market sounding indicates a valuation of
    CANNORDIC A/S of MDKK 224 (EUR 30 million).

  * Market Positioning: The spin-off aims to enhance the market positioning
    of both entities.

  * Shareholder Approval: The transaction is subject to approval at an
    extraordinary general assembly.

  * Transaction Timeline: The transaction and stock market listing are
    planned to be completed by the end of 2024.

"The decision to list CANNORDIC A/S on the German stock market is a
strategic milestone for us. This spin-off underscores the commitment to
leveraging market opportunities and aligning operations with the stringent
requirements of the new EU MDR (Medical Device Regulation), ensuring
sustained growth and market leadership. Additionally, it highlights the
value of CS MEDICA's stock and will enhance our market presence, providing
the necessary funding to accelerate our growth and innovation objectives",
stated Lone Henriksen, CEO of CS MEDICA A/S.

Background Information for the Suggested Strategic Initiatives

CS MEDICA is a Group specializing in IPR management and strategic oversight,
supporting its entities, while CANNORDIC specializes in R&D, MDR compliance,
registration, manufacturing, and commercialization for greater efficiency.

"By listing CANNORDIC on the German Stock Exchange, we aim to advance its
profile and reach its right potential in market valuation, attracting
investors and partners on the most mature, well-fitted market in Europe for
the Company's portfolio. This strategic initiative is expected to unlock the
potential market value, increasing shareholder value for both the CS MEDICA
Group and CANNORDIC. By raising up to MDKK 45 (EUR 6 million), we will also
secure growth capital to accelerate and strengthen our market position."
Lone Henriksen continues.

The extraordinary general assembly to approve this transaction is scheduled
for June 2024. Additional details regarding the planned spin-off of the
wholly-owned subsidiary CANNORDIC A/S will be published throughout the IPO
process to keep all stakeholders informed and up to date.

About CS MEDICA A/S

CS MEDICA, a Danish MedTech pioneer, specializes in developing
evidence-based, CBD-integrated treatments for pain management, autoimmune
and stress-related disorders. With a focus on patient-centric care, our
products range from innovative R&D to registered over-the-counter
substance-based medical devices and dermaceuticals. Our flagship CANNASEN®
brand, alongside our own-label solutions, exemplifies our dedication to
safe, high-quality treatments for both human and veterinary health globally.

The Group company is listed on Spotlight Stock Market in Stockholm (symbol:
"CSMED"). For more information, visit cs-medica.com and LinkedIn.

https://www.cs-medica.com/

About CANNORDIC A/S

CANNORDIC, a subsidiary of CS MEDICA Group, is a pioneering MedTech company
specializing in innovative substance-based medical devices containing
bioactive CBD. Our dedication to enhancing lives by integrating innovation,
science, technology, and natural cannabis compounds positions it as a
pioneer in the medical technology industry. The company ensures robust
research, development, manufacturing, compliance, data insights, and
commercialization processes.

www.cannordic.com


End of Inside Information

---------------------------------------------------------------------------

10-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        CS MEDICA
                   Indiakaj 10,2
                   2100 Copenhagen
                   Denmark
   Phone:          +45 70707337
   E-mail:         info@cs-medica.com
   Internet:       https://www.cs-medica.com
   ISIN:           DK0061668225
   WKN:            A3CYEQ
   Listed:         Regulated Unofficial Market in Frankfurt, Munich,
                   Stuttgart
   EQS News ID:    1921743

End of Announcement EQS News Service
---------------------------------------------------------------------------

1921743 10-Jun-2024 CET/CEST